MilliporeSigma today announced the expansion of its state-of-the-art single use current good manufacturing process (cGMP) facility with the addition of the Mobius® 2000L single-use bioreactor. With the new upstream suite at its Biodevelopment Center in France, MilliporeSigma can now offer clients full process line cGMP manufacturing, comprised of MilliporeSigma’s own instrumentation and products. “Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production,”…